Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG002 in HPV16/18 Associated CIN2/3
NCT06273553Phase 2Not yet recruiting
- Sponsor
- RinuaGene Biotechnology
- Start
- Mar 2024
- Primary completion
- Oct 2026
- Modality
- Conjugated siRNA, mRNA Therapeutics, Small Molecules
01
Overview
A Phase 2 trial of RG002 in cervical intraepithelial neoplasia (CIN), sponsored by RinuaGene Biotechnology. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
RG002
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT06273553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06273553.